Myasthenia gravis is not typically a death sentence, but it does carry real mortality risk. In a large study tracking 422 patients, 14% died within five years of diagnosis and 21% within ten years, rates significantly higher than the general population. Both men and women with MG die younger on average: men at 78.3 years compared to 81.6 in the general population, and women at 76.5 compared to 85.2.
How MG Can Become Life-Threatening
The danger comes from what the disease does to muscles you need for breathing and swallowing. MG weakens voluntary muscles by disrupting the signal between nerves and muscle fibers. When this affects the diaphragm and the muscles between your ribs, your lungs can’t move enough air. When it affects the throat and tongue, you can choke on food or liquid, or inhale material into your lungs that causes pneumonia.
The most dangerous scenario is called myasthenic crisis, where breathing muscles weaken to the point that you need a ventilator. Patients who require intubation during a crisis face substantially worse outcomes: mortality in the intubated group reached 46%, compared to 27% in those who didn’t need mechanical ventilation. Crisis can be triggered by infections, surgery, certain medications, or simply a worsening of the disease itself.
What Actually Causes Death
MG rarely kills through a single dramatic episode. The leading cause of death is infection, accounting for 52% of fatalities in one detailed analysis. The connection works in two directions: weakened swallowing and breathing muscles make you more vulnerable to respiratory infections, and those infections then worsen the existing muscle weakness, creating a dangerous cycle. Aspiration pneumonia, where food or liquid enters the lungs, is a particular risk.
There’s also a significant link to long-term steroid use. Among patients who died from infections, 92% had been on chronic steroid therapy, compared to 58% of the overall patient group. Steroids suppress the immune system, which is partly why they help control MG, but that same immune suppression leaves patients more exposed to serious infections over time. Other causes of death included cancer (23%) and cardiovascular disease (15%).
Factors That Raise or Lower Risk
Several factors influence how dangerous MG is for a given person. Patients with thymoma, a tumor of the thymus gland that sometimes accompanies MG, have a worse prognosis due to the malignancy itself, higher rates of second cancers, surgical complications, and additional autoimmune conditions.
Thymectomy, the surgical removal of the thymus, appears protective. Mortality was 19% in patients who had the surgery compared to 35% in those who kept their thymus. Bulbar symptoms at the time of diagnosis, meaning difficulty swallowing, nasal-sounding speech, and jaw weakness, also trend toward higher mortality, though the statistical significance isn’t definitive.
Warning Signs of a Crisis
Recognizing a myasthenic crisis early is one of the most important things you can do. The warning signs involve both breathing and swallowing. On the breathing side, watch for increasing shortness of breath, visible straining of neck and shoulder muscles with each breath, and a weak cough. A simple bedside test: if you can’t count to 20 in a single breath, your expiratory muscles are significantly weakened.
Swallowing problems are equally important. Difficulty getting food down, liquid coming back through the nose, speech that sounds nasal or choppy, and weakness when trying to close the jaw all signal that the muscles controlling the throat and airway are failing. These symptoms can escalate over hours or days, and any combination of worsening breathing with swallowing trouble warrants emergency care.
Modern Treatments and Outlook
Treatment for MG has changed substantially in recent years with the approval of targeted biological therapies. Complement inhibitors and a newer class of drugs that lower harmful antibody levels have given patients options beyond traditional steroids and broad immune suppressants. In clinical trials and real-world use, between 86% and 100% of patients on these newer therapies achieved meaningful improvement. Case reports have even shown these drugs helping patients wean off ventilators after a myasthenic crisis.
Current treatment guidelines now recommend starting these targeted therapies earlier, especially in patients with high disease activity, rather than reserving them as a last resort. The goal for most patients has shifted from simply controlling symptoms to reaching “minimal manifestation status,” where the disease has little to no impact on daily life.
Despite this progress, the numbers tell a sobering story. Mortality rates have not significantly improved over the past two decades. Comparing patients diagnosed before 2010, between 2010 and 2020, and after 2020, three-year mortality rates remained statistically similar across all groups. The newest targeted therapies may eventually change this trend, but as of now, the survival data hasn’t caught up with the treatment advances. MG remains a condition that demands consistent management, awareness of crisis warning signs, and careful attention to the risks that come with long-term immunosuppressive treatment.